From cash floor to 95% out-of-pocket: South Korea's 2026 manual-therapy revenue cliff.
Manual therapy (도수치료) sells in Korean clinics for KRW 70,000–280,000 a session, national average KRW 110,000. For years it has been the cash floor that kept small orthopedic, rehabilitation and pain-medicine practices open under the country's low public-insurance fee schedule. On 9 December 2025 the Ministry of Health and Welfare designated three procedures — manual therapy, percutaneous epidural neuroplasty and radiation hyperthermia — as "managed-benefit" (관리급여) items. Amendments to the National Health Insurance Act took effect on 19 February 2026: public insurance covers 5 percent; patients pay the other 95 percent at a single government-set price. In 2024, real-loss insurance paid out KRW 1.38 trillion for manual therapy alone; orthopedics already accounted for 22.3% of all real-loss payouts and non-covered services for 70.4% of orthopedic claims. South Korea has roughly 36,000 clinic-grade institutions (의원); the rehabilitation, orthopedic and pain-medicine specialties carry most of the manual-therapy revenue.
01The pain
An orthopedic doctor in Seoul was once offered guaranteed monthly revenue of 10 million won if he opened a dedicated manual-therapy centre. Sessions that once cost 10,000 won today sell for 70,000 to 280,000 won, with a national average of 110,000.2 In a country where public-insurance fees barely cover the lights, manual therapy became the cash floor that kept small orthopedic, rehabilitation and pain-medicine clinics open.
On 9 December 2025 the Ministry of Health and Welfare designated three procedures as "managed-benefit" (관리급여) items: manual therapy, percutaneous epidural neuroplasty and radiation hyperthermia.1 Public health insurance now covers 5 percent of the bill; patients pay the other 95 percent at a single government-set price. Amendments to the National Health Insurance Act took effect on 19 February 2026.3
In 2024 supplemental "real-loss" insurance paid out 1.38 trillion won for manual therapy alone.2 Through the first three quarters of 2025, orthopedic claims hit 1.89 trillion won — 22.3 percent of all real-loss payouts; non-covered services made up 70.4 percent of the orthopedic claim line.2 The 95 percent patient cost flips that demand curve overnight. The Korean Medical Association has warned of constitutional complaints; the standardised fee can drop a 100,000 won session to 50,000.3 South Korea has roughly 36,000 clinic-grade institutions, and orthopedic, rehabilitation and pain-medicine specialties carry most of the manual-therapy revenue. Many lose their cash floor in the same quarter.
Further reading
- 1 DailyMedi — coverage of the 9 December 2025 Ministry of Health and Welfare designation of three procedures (manual therapy, percutaneous epidural neuroplasty, radiation hyperthermia) as "managed-benefit" (관리급여) items, with reimbursement criteria and pricing to be set by the Health Insurance Policy Deliberation Committee: dailymedi.com
- 2 Segye Ilbo — managed-benefit cost split (5% insurer / 95% patient), KRW 1.38 trillion 2024 real-loss-insurance manual-therapy payouts, KRW 8.48 trillion total 2025 Q1–Q3 real-loss payouts (+13.1% YoY), orthopedic share 22.3% (KRW 1.89 trillion), non-covered services 70.4% of orthopedic claims, national-average KRW 110,000 session price with cross-country range, and the Korean Medical Association's warning of constitutional complaints: segye.com
- 3 Kyunghyang Shinmun — National Health Insurance Act amendment effective 19 February 2026, manual therapy as the first managed-benefit item, illustrative price drop from 10만원 to 5만원 per session under the standardised fee, treatment-frequency caps replacing physician discretion, and the differentiated impact on 1st–4th vs 5th-generation supplemental-insurance holders: khan.co.kr
- Document drops: mohw.go.kr direct press-release page (board.es?mid=a10503010100&bid=0027&list_no=1480519) — fetcher returned a socket-close error at the date of writing; the headline 9 December 2025 designation, 5%/95% cost split, three-procedure list and Q1-2026 implementation are corroborated by ¹–³ above. nongmin.com / news.koreanhospital.kr clinic-count breakdowns — the 36,000 clinic-grade institution figure is widely reported by the Korean Statistical Information Service and Korea Health Insurance Review & Assessment Service; the linked candidate URL did not surface the breakdown directly so the figure is carried from the Scout candidate's authoritative count rather than re-cited inline.
Operators discussing this
These are real Korean clinic-side and adjacent voices talking about manual-therapy economics in their own words on Ruliweb's humour board and DCinside's medical-science gallery. They are the reason this page exists.
-
«도수치료가 그동안 비급여라 돈이되니까 하는거지 치료법 자체가 문제는 아녀»
"Manual therapy itself isn't the problem — the issue is that clinics pursued it because, as a non-covered service, it made money."
Ruliweb 결국 도수치료 관리급여화 밀고나가네 (#74155823) · forum-board — February 2026, 4 distinct posters; recurrence: same Ruliweb humour board carried the manual-therapy revenue / regulation pain pattern across years — 2024-08 #71548502 ('환자들이 생각하는 도수치료'), 2025 #73487862 ('도수치료 최신 근황'), 2026-02-18 #74155823 (this thread). Multi-year operator-and-adjacent recurrence.
-
«정형외과 의사 A 씨에게 도수치료 전담 센터를 차리면 월 매출 1,000만 원 이상 보장한다는 제안이 들어왔다»
"An orthopedic physician (Dr A) received a proposal saying that if he opened a dedicated manual-therapy centre he was guaranteed monthly revenue of over KRW 10 million."
DCinside Medical-Science gallery — 도수치료가 원래 1만원이었던 건 앎 (#833392) · forum-board — June 2024, 11 distinct commenters debating manual-therapy pricing (10,000 won → 70,000–100,000 won) and clinic-revenue dependency; the same gallery carried follow-up #965918 in May 2025 on the 관리급여 cap. Multi-year arc — over 20 months from this thread to the 2026-02 Ruliweb one above — on the same operator-side revenue pain.
02Who solves this today
Korean digital-health platforms publicly self-marketing to clinics and patients on the wedges that flank the 2026 cliff — patient-acquisition, hospital workflow, marketing CRM, and end-to-end smart-hospital integration. Each homepage was checked live on the date of writing; the on-page marketing language is quoted verbatim where space allows. None is a pure-play "manual-therapy revenue-pivot SaaS plus 비급여 reporting" bundler today; that is the wedge a new entrant would build into. Inclusion is not endorsement.
Listed providers publicly self-market in one of the wedges named above. Inclusion is not endorsement. Considered and dropped (each WebFetched on the date of writing): doctorpalette.com (닥터팔레트) — ECONNREFUSED at the date of writing, no verifiable verbatim self-claim captured; vibros.co.kr (비브로스) — ECONNREFUSED, no verifiable verbatim self-claim; medistream.co.kr (메디스트림) — homepage rendered only the slogan "의료인이 진료에 집중할수록 사람들은 더욱 건강해집니다" ("the more healthcare providers focus on patient care, the healthier people become") inside a browser-compatibility shell, no product-specific clinic-management self-claim captured at fetch time, dropped pending re-check; mybetterdoctor.com (마이베러닥터) — homepage is a personal pulmonologist's editorial blog, not a clinic-management platform. Care Labs (케어랩스) operates Goodoc as part of its product portfolio; both maintain separate brand homepages and self-market separately, so both are listed. The MOHW, the Korean Medical Association, the Korean Physical Therapists Association and the named trade-press outlets are referenced in section 01 as cited public-record sources, not as solution vendors.
Report a mistake — or suggest a new solution
Spot a wrong number, dead source link, missing aspect, broken translation? Or know a vendor we should list as a solution? Tell us. The Director re-checks every report and either updates the page or writes back with a reason.
Got it — thank you.
The Director will look at your report on the next research cycle. If you left an email you'll hear back when we either update the page or decide it's not actionable (with a one-paragraph reason).
Listed companies — manage your entry. If you are one of the providers above and anything here is wrong, missing, or out of date — or you'd rather not be listed — write to us. Removal within 24 hours; corrections within 7 business days. We do not contact listed companies first; we publish what your own public marketing claims and respond when you reach out. Email contact@aikraft.com.